Big Eye Diagnostics specializes in field-deployable diagnostics made to withstand tough conditions. Our vision is to bring rapid tests, for which prototypes exist and have been developed either by third parties or internally, through manufacturing and commercialization. 

Big Eye Diagnostics was launched in 2022 with funding from the National Institutes of Health (NIH) as an offshoot of Drugs and Diagnostics for Tropical Diseases (DDTD)and is proud to have been awarded three Small Business Innovation Research Grants in a short timespan.

  • Rapid test for lymphatic filariasis (Phase I/II Fast-Track: R44AI170131)
  • Rapid test for paragonimiasis (Phase I: R43AI172459)
  • Rapid test for onchocerciasis (Direct-to-Phase II: R44AI174495)